{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"47"}],"title":"Residual disease"},{"measurements":[{"groupId":"OG000","value":"40"}],"title":"No residual disease"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"87"}],"units":"Participants"}],"description":"Logistic regression will be used to analyze the significant association between standardized phase angle and marrow response at 14-day bone marrow biopsy to show the odds of having 14-day residual disease (presence cancer cells remaining after treatment) and non-residual disease (no cancer cells remaining after treatment). (14 day bone marrow response is defined as hypoplastic marrow with less than 20% cellularity and 5% blasts. Complete remission is defined as less than 5% marrow blasts, absolute neutrophil count \\>1000, platelet count \\>100,000 and freedom from red cell transfusions).","groups":[{"description":"Patients undergo bioelectrical impedance phase angle measurement on day 1 of treatment. Patients with AML undergo a second measurement just prior to the nadir marrow. Patients also undergo bioelectrical impedance measurements prior to any invasive procedures (bone marrow biopsy, leukapheresis, PICC line placement, etc.).\n\nbioelectric impedance analysis: Undergo bioelectric impedance analysis","id":"OG000","title":"Diagnostic (Bioelectric Impedance Analysis)"}],"paramType":"COUNT_OF_PARTICIPANTS","populationDescription":"14 participants excluded in analysis due to 14-day bone marrow data not available.","reportingStatus":"POSTED","timeFrame":"14 days","title":"Number of Participants With Bone Marrow Response","type":"SECONDARY","unitOfMeasure":"Participants"}